Merck to Acquire Cubist Pharmaceuticals: What It Means for Mutual Fund Investors (MRK, CBST)

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Merck & Company logo

News

Merck to Acquire Cubist Pharmaceuticals: What It Means for Mutual Fund Investors (MRK, CBST)

Shauna O'Brien Dec 08, 2014

Merck (MRK) announced on Monday morning that it has agreed to purchase Cubist Pharmaceuticals (CBST). Here’s what the news means for mutual funds investors.

Inside the Deal

Merck announced that it will purchase the antibiotics maker for $8.4 billion in cash. The news sent shares of Cubist Pharmaceuticals soaring over 35% on Monday morning.

Cubist focuses on drugs that treat infectious diseases, usually in a hospital setting. According to Cubist, it plans to release four new drugs by 2020. This purchase will allow MRK to continue its strategy to focus on areas including diabetes, acute hospital care, vaccines and oncology.


Mutual Funds to Watch

The funds listed below currently hold the largest stake in Cubist Pharmaceuticals. These funds may be a good alternative to buying the individual stock.
The funds below currently have the largest stakes in Merck:

The Bottom Line

The funds above allow investors to gain exposure to Merck and Cubist, as well as many other holdings and industries. Investors investing in health care focused mutual funds may also consider Fidelity Select Health Care Portfolio (FSPHX) and T. Rowe Price Health Sciences Fund (PRHSX).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book